APA (7th ed.) Citation

Gutiérrez-Chamorro, L., Felip, E., Castellà, E., Quiroga, V., Ezeonwumelu, I. J., Angelats, L., . . . Margelí, M. (2024). SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer. Cellular Oncology (2211-3428), 47(1), 189. https://doi.org/10.1007/s13402-023-00862-1

Chicago Style (17th ed.) Citation

Gutiérrez-Chamorro, Lucía, et al. "SAMHD1 Expression Is a Surrogate Marker of Immune Infiltration and Determines Prognosis After Neoadjuvant Chemotherapy in Early Breast Cancer." Cellular Oncology (2211-3428) 47, no. 1 (2024): 189. https://doi.org/10.1007/s13402-023-00862-1.

MLA (9th ed.) Citation

Gutiérrez-Chamorro, Lucía, et al. "SAMHD1 Expression Is a Surrogate Marker of Immune Infiltration and Determines Prognosis After Neoadjuvant Chemotherapy in Early Breast Cancer." Cellular Oncology (2211-3428), vol. 47, no. 1, 2024, p. 189, https://doi.org/10.1007/s13402-023-00862-1.